Biotechnology & Drugs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology & Drugs

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: 2MAR$ who wrote (221)	2/28/2004 4:48:21 PM
From: 2MAR$	of 232

1/22 Amgen misses by $0.02, ex items (AMGN) 62.00 -0.81: Reports Q4 (Dec) earnings of $0.46 per share, ex items, $0.02 worse than the Reuters Research consensus of $0.48; revenues rose 32.9% year/year to $2.35 bln vs the $2.34 bln consensus. 20-Jan-04 08:56 ET In Play Abgenix announces ABX-EGF enters pivotal trial in Advanced Colorectal Cancer patients (ABGX) 15.35: Co announces that its partner, Amgen (AMGN), is beginning a pivotal trial for its fully human monoclonal antibody, ABX-EGF, as a third-line monotherapy in colorectal cancer patients, with enrollment expected to begin shortly. The trial initiation follows the receipt of a Special Protocol Assessment (SPA) letter from the FDA. 09-Jan-04 13:03 ET In Play Amgen Inc - - 200 Day Alert (AMGN) 63.75 +0.39: -- Technical -- The stock is testing its 200-day simple movinge average (63.79) resistance for a second day in a row. Amgen extends early run rally, nearing Jan high of 65.73 (AMGN) 65.61 +0.96: -- Technical -- Stock able to build on the early push with it approaching resistance at its Jan/three month high of 65.73 (session high 65.64). 26-Jan-04 13:41 ET In Play Amgen tests last wk's high of 64.30 (AMGN) 64.26 +0.33: -- Technical -- Stock has crossed back above its 200 day avg and is vacillating near last wk's high of 64.30. If able to stage a clean break, the door will be open to the three month high set earlier in the month at 64.49. 23-Jan-04 14:19 ET In Play 200 Day-Alert -- Amgen (AMGN) 63.78 +2.31: -- Update -- -- Technical -- Solid advance today despite downgrade (see 08:36 update) with the stock nearing resistance at its 200 day simple mov avg at 63.98 (session high 63.85). 23-Jan-04 08:36 ET In Play AMGN cut to Peer Perform at Thomas Weisel 61.47: Thomas Weisel downgrades Amgen (AMGN) to Peer Perform from Outperform and reduces price tgt to $70 from $80. Firm says lower product sales and corporate partner revenue combined with higher operating expenses led to the shortfall versus firm's estimate. Co's key anemia and neutropenia franchises seem to be maturing and firm believes future Enbrel growth will come from areas outside of the relatively saturated rheumatoid arthritis market

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next